Neutrophils and monocytes/macrophages are derived from common progenitors, but exhibit markedly different lifespans. Differentiated neutrophils are short-lived and die rapidly by apoptosis, while monocytic cells are longer-lived. In this report we used the HL-60 cell line as a model system to identify differences in apoptotic pathways which might account for the differing lifespans of granulocytic vs monocytic cells. We observed that induction of granulocytic differentiation by retinoic acid led to robust activation of the executioner protease caspase-3, and early onset of apoptosis. By contrast, caspase-3 was not appreciably activated during phorbol 12-myristate 13-acetate (PMA)-induced monocytic differentiation, and apoptosis was delayed in these cells. Since the activation of caspase-3 is inhibited by members of the inhibitor of apoptosis (IAP) and Bcl-2 protein families, we investigated the expression of anti-apoptotic members of these families. Induction of monocytic differentiation led to marked upregulation of the IAP protein XIAP, as well as the Bcl-2 family member Bcl-X L . During granulocytic differentiation the levels of XIAP progressively declined, while Bcl-X L levels remained unchanged. A different IAP protein, survivin, was downregulated during differentiation along either lineage, as was expression of Bcl-2. The upregulation of Bcl-X L during monocytic differentiation coincided with phosphorylation/activation of STAT3, a known activator of bcl-X gene transcription. Moreover, Bcl-X L upregulation was dependent on MEK/ERK signaling. Upregulation of XIAP proceeded in a MEK/ERK-independent fashion. Treatment with antisense Bcl-X L or XIAP oligonucleotides resulted in significant loss of viability in cells differentiating along the monocytic lineage. Together, these findings indicate that the levels of XIAP and Bcl-X L are regulated by distinct pathways during monocytic differentiation, and that upregulation of these proteins contributes to the increased longevity of cells in the monocytic lineage.
Introduction
Neutrophils and macrophages are important components of the host defense system, playing key roles in the phagocytosis and destruction of invading microorganisms. These specialized cells are derived from myeloid progenitors, neutrophils by granulocytic differentiation and macrophages by monocytic differentiation. During an infection, the levels of circulating, differentiated myeloid cells increase dramatically due to cytokine-mediated effects on the proliferation, survival, and differentiation of progenitor populations. Attenuation of an inflammatory response, on the other hand, is brought about by apoptosis, a controlled biological process leading to the Caspases are normally present in the cell as inactive proenzymes, which can be activated by selective proteolytic cleavage. Treatment of cells with an apoptotic stimulus results firstly in the activation of initiator caspases. Once activated, initiator caspases cleave and activate downstream executioner caspases, such as caspase-3. [7] [8] The executioner caspases are responsible for the cleavage of specific cellular substrate proteins, resulting in the destruction of the cell. 6, 9 Members of the Bcl-2 protein family are key intracellular regulators of caspase activation and apoptotic pathways. 10 Bcl-2 and Bcl-X L , two anti-apoptotic members of this family, exert their effects by preventing the release of cytochrome c from mitochondria into the cytosol in cells receiving an apoptotic stimulus. 11, 12 Since cytochrome c release normally results in activation of the initiator caspase, caspase-9, followed by activation of caspase-3, 7, 13 Bcl-2 and Bcl-X L effectively prevent triggering of the caspase cascade. Pro-apoptotic members of the Bcl-2 protein family, including Bax, Bad, Bak and Bid, promote cytochrome c release and the activation of caspases.
A second important family of apoptosis regulators is the inhibitor of apoptosis protein (IAP) family. To date, six different human IAP family proteins have been described (NAIP, cIAP-1, cIAP-2, XIAP (or hILP), survivin, and BIR repeat-containing ubiquitin-conjugating enzyme (BRUCE)). 14, 15 In the cases of c-IAP-1, c-IAP-2 and XIAP, it has been demonstrated that these molecules inhibit apoptosis by binding and inhibiting selective caspases, namely, caspase-3, caspase-7 and caspase-9. [16] [17] [18] [19] To investigate potential differences in apoptotic pathways which may account for the differing lifespans of monocytic vs granulocytic cells, we employed the model cell line HL-60. HL-60 cells are acute myeloid leukemic cells, which can be induced to differentiate along the monocytic lineage by treatment with phorbol 12-myristate 13-acetate (PMA) or along the granulocytic lineage by treatment with retinoic acid (RA). 20, 21 As expected, we observed that induction of granulocytic differentiation led to a more rapid onset of apoptosis and loss of 391 viability than was seen during monocytic differentiation. The early onset of apoptosis during granulocytic differentiation correlated with earlier and more robust activation of caspase-3 in these cells. By contrast, monocytic differentiation was distinguished by upregulation of Bcl-X L (albeit not Bcl-2) protein levels, as has been previously observed. 22 Induction of monocytic differentiation also led to the activation of STAT3, which may be responsible for the increased Bcl-X L expression. 23 In addition to Bcl-X L upregulation, we also observed increased expression of XIAP protein during monocytic differentiation, with no corresponding increases seen during granulocytic differentiation. The upregulation of Bcl-X L and XIAP may account for the delayed activation of caspase-3 we observed in the monocytic cells. By employing antisense oligonucleotides directed against Bcl-X L or XIAP mRNAs, we determined that upregulation of Bcl-X L and XIAP contributes to the enhanced survival of cells differentiating along the monocytic lineage. Finally, the impact of MEK/ERK signaling on Bcl-X L and XIAP expression levels was also investigated. Together, our findings point to important differences in the regulation of apoptotic pathways during monocytic vs granulocytic differentiation that may explain the differing lifespans of cells derived from these two lineages.
Materials and methods

Reagents
Phorbol 12-myristate 13-acetate (PMA) and retinoic acid (RA) were purchased from Sigma Chemical (St Louis, MO, USA). PMA was dissolved in dimethyl sulfoxide (DMSO) and RA in ethanol. Stock solutions were stored at −20°C. PMA or RA was added to cultures at a 1:1000 dilution, and control cultures received either DMSO or ethanol at the 1:1000 dilution. The MEK-1/-2 inhibitor, U0126, was obtained from Cell Signaling Technology (Beverly, MA, USA) and dissolved in DMSO to achieve a 10 mM stock solution. APO-BRDU DNA fragmentation kits for measuring apoptosis were obtained from BD Pharmingen (San Diego, CA, USA). The caspase-3 assay kit was purchased from Medical & Biological Laboratories (Nagoya, Japan). Protein A Sepharose was obtained from Sigma Chemical.
Antibodies
The anti-Bcl-2 monoclonal antibody was purchased from DAKO (Carpinteria, CA, USA) and anti-XIAP monoclonal antibody was purchased from Transduction Laboratories (Lexington, KY, USA). Polyclonal antibodies against STAT3 (for immunoprecipitation and gel shift assays) were obtained from Upstate Biotechnology (Lake Placid, NY, USA) and Santa Cruz Biotechnology (San Jose, CA, USA). Monoclonal antibody against total STAT3 protein was obtained from Transduction Laboratories and polyclonal antibody against Bcl-X L was obtained from Santa Cruz Biotechnology. Monoclonal antiphospho-STAT3 (phospho-Tyr 705) was purchased from Upstate Biotechnology. Polyclonal anti-survivin antibody was obtained from Novus Biologicals (Littleton, CO, USA). Phycoerythrin-labeled anti-CD11b antibody (CD11b-PE) and polyclonal anti-caspase-3 were from BD Pharmingen (San Diego, CA, USA). Monoclonal anti-␤-actin antibody was purchased from Sigma Chemical. The HRP-conjugated secondary antiLeukemia bodies for Western blotting were obtained from Promega (Madison, WI, USA).
Cell culture and treatment
The acute myeloid leukemia cell line, HL-60, was obtained from the American Type Culture Collection (Richmond, MD, USA). Cells were maintained in RPMI 1640 medium (Gibco BRL, Grand Island, NY, USA) containing 10% heat-inactivated fetal bovine serum (FBS) (Gibco/BRL). For induction of monocytic differentiation, HL-60 cells in logarithmic phase of growth were pelleted and resuspended at 3 X 10 5 /ml in fresh media containing 20 ng/ml PMA (final concentration of DMSO in the culture medium was 0.1%). Control cultures were treated similarly with DMSO alone. PMA-treated cells and control cells were harvested and analyzed on days 1, 3, 5 and 7. For induction of granulocytic differentiation, RA was added to HL-60 cultures to a final concentration of 5 M, with control cultures receiving ethanol alone. RA-treated and ethanol-treated cells were harvested on days 1, 3, 5 and 7. In experiments where U0126 was used to study the importance of the MEK/ERK kinase pathway, HL-60 cells were incubated for 2 h with 5 M of U0126 prior to the addition of PMA or RA.
Assays for differentiation
Reduction of nitroblue tetrazolium (NBT) was used to assess granulocytic differentiation, and staining for non-specific esterase (NSE) was used to assess monocytic differentiation. 24, 25 For each timepoint examined, a total of 200 cells was counted under oil immersion from five different fields. The percent of cells differentiated into granulocytes or monocytes was calculated by dividing the number of positive cells by the total number of cells counted.
Differentiation was also assessed by flow cytometric analysis of CD11b expression. Cells treated with either PMA or RA were washed with PBS and incubated with PE-labeled antiCD11b monoclonal antibody for 30 min on ice. Non-specific staining was determined using isotype antibody controls (BD Pharmingen). After incubation with antibody, cells were washed twice in PBS containing 1% FBS and 0.1% azide, and fixed in 1% paraformaldehyde. Flow cytometric analysis was performed on an Epics Coulter XL equipped with a 488 nm argon laser. A total of 10 000 cells were analyzed for each sample.
Determination of cell viability and apoptosis
Cell viability was determined by trypan blue exclusion. While this was easily done for RA-treated cultures, PMA treatment led to adherence of cells to the plate, and these cells needed to be detached using 0.25% trypsin/EDTA (Gibco/BRL) and cell scraping. Following scraping, the dislodged cells were combined with the floating or non-adherent cell population, and viabilities were determined on the total population using trypan blue. For each timepoint, a total of 100 cells was counted in triplicate and viabilities were presented as the mean ± standard deviation.
Apoptotic cell death was measured using the TUNEL (TdTmediated dUTP nick end labeling) assay. TUNEL assays were performed using the APO-BRDU labeling kit from BD Pharmingen, according to the manufacturer's instructions. Flow cytometric analyses were performed using the Epics Coulter XL. For each sample, 20 000 events were collected and analyzed.
Preparation of cell lysates and immunoblotting
Treated cells were harvested by centrifugation at various timepoints, washed twice in phosphate-buffered saline (PBS), and lysed in buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 0.1% SDS, 1.0% NP-40, 1.5 mM PMSF, 3 g/ml leupeptin and 20 g/ml aprotinin. The supernatants were recovered by microcentrifugation at 14 000 r.p.m. for 2 min and stored at −80°C.
For preparation of cell extracts for phosphoprotein analysis, a modified lysis buffer was employed. In this case, cells were washed with cold PBS followed by lysis in a buffer containing 20 mM Hepes pH 7.5, 150 mM NaCl, 1 mM EGTA, 1.5 mM MgCl 2 , 10% glycerol, 1% Triton X-100, 1 mM PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin, 50 mM NaF, 2 mM sodium orthovanadate and 10 mM sodium pyrophosphate. The lysed cells were incubated on ice for 30 min, then subjected to microcentrifugation at 14 000 r.p.m. for 10 min at 4°C. The resulting supernatants were either utilized immediately or stored at −80°C.
To perform immunoblot analyses, equal quantities of protein extracts (30-50 g/lane) were boiled in an equal volume of 2X sample buffer, resolved on 12.5% SDS/PAGE gels, then transferred to nitrocellulose membranes (Millipore, Bedford, MA, USA). Non-specific binding was blocked by incubating membranes with 5% low fat milk solution prepared in Trisbuffered saline (TBS pH 8.0) containing 0.1% Tween-20 (TBS-T). The blocked filters were probed with primary antibodies either for 1 h at room temperature or for overnight at 4°C (phospho-specific antibodies). After four washes with TBS-T, the membranes were incubated with conjugated secondary antibodies for 1 h at room temperature. The membranes were then washed an additional four times in TBS-T, followed by detection of the immunoreactive proteins by enhanced chemiluminescence (New England Nuclear, Boston, MA, USA).
Immunoprecipitation
Cells were harvested by centrifugation at various timepoints, washed twice in PBS, and lysed in RIPA buffer containing protease and phosphatase inhibitors (50 mM Tris, pH 7.2, 150 mM NaCl, 1% deoxycholate, 0.1% SDS, 1% Triton X-100, 0.25 mM EDTA, 5 mM sodium fluoride, 100 M sodium orthovanadate, 1 mM PMSF, 5 g/ml leupeptin, 2 g/ml pepstatin and 1 g/ml aprotinin). Lysates were incubated on ice for 10 min followed by centrifugation at 14 000 r.p.m. for 10 min. Protein concentrations were determined using the BioRad Protein assay (Bio-Rad, Hercules, CA, USA) and 500 g of protein from each sample was incubated overnight with 4 g of anti-STAT3 antibody at 4°C. Protein A Sepharose was then added to the immune complex and incubation continued for 1 h. After three washes with RIPA buffer, 2X sample buffer was added and the beads were boiled for 5 min. The samples were centrifuged and the resulting supernatant was resolved on an 8% SDS-PAGE gel, followed by transfer to nitrocellulose. The membrane was blocked with 3% milk/PBS-T for 1 h and then incubated with anti-phosphoSTAT3 (Tyr 705) antibody overnight at 4°C. After incubation with peroxidase-conjugated secondary antibody for 1 h, the blot was developed using ECL. The membrane was stripped and reprobed with anti-STAT3 antibody.
In vitro caspase-3 assay
To assay caspase-3 activity in treated and untreated cells, 5 x 10 6 cells were harvested at various timepoints, pelleted, resuspended in 50 l of chilled lysis buffer (Medical & Biological Laboratories), then incubated on ice for 10 min. The lysates were then centrifuged at 10 000 g for 1 min, and the supernatants were transferred to new tubes on ice. Protein concentrations were determined using the Bio-Rad Protein assay and 100 g of protein from each sample was diluted with cell lysis buffer to 50 l. To each sample was then added 50 l of 2X reaction buffer (containing 10 mM DTT) and 5 l of the DEVD-pNA substrate (200 M final concentration), and the reactions were allowed to incubate at 37°C for 3 h. Following incubation, absorbance values at 405 nm were determined using a microtiter plate reader.
Electrophoretic mobility shift assay (EMSA)
Cells were pelleted and lysed for 10 min in 20 l of buffer (400 mM NaCl, 1.5 mM MgCl 2 , 20 mM Hepes (pH 7.9), 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol (DTT), 10% glycerol, 0.2% NP-40, 2 mM Na 3 VO 4 , 10 mM NaF, 1 g/ml leupeptin, 1 g/ml pepstatin A, 1 g/ml aprotinin and 0.5 mM PMSF). Freeze thawing of lysates was repeated twice and whole cell extracts (WCE) were collected after centrifugation at 21 000 g for 15 min at 4°C. Protein concentrations were determined by the Bio-Rad Protein assay. Equal quantities of protein were assayed for DNA binding by EMSA. Briefly, 45 g WCE were incubated with 1 pg of ␥-32 P-ATP-labeled, double-stranded 19 bp SIE-like element (hSIE) (2500 c.p.m./fmol) from the promoter region of the c-fos gene. Incubations were allowed to proceed for 20 min at room temperature in 20 l of EMSA buffer (12 mM Hepes (pH 7.9), 60 mM KCl, 5 mM MgCl 2 , 10% glycerol, 1 mM DTT, 0.1 mM EDTA and 0.1 g/l poly (dI-dC)). Samples were resolved on a 4% polyacrylamide gel for 1.5 h at 200 V in 0.5X TBE buffer. Gels were dried and exposed to X-ray film. For supershift studies, 1 g of polyclonal anti-STAT3 antibody was added to the reaction and incubated at 4°C for 1 h before the addition of the labeled probe.
Antisense treatment
Morpholino antisense Bcl-X L (5'-CCAGCTCCCGGTTGCTCTG AGACAT-3'), mis-paired Bcl-X L control (5'-CCTGCTGCCGGT TGCTCAGAGTCAT-3') and antisense XIAP (5'-TCCTTCAAAA CTGTTAAAAGTCATC-3') oligonucleotides paired to a complementary DNA were purchased from Gene Tools, LLC (Philomath, OR, USA). The mis-paired Bcl-X L control oligonucleotide contained four base changes relative to wild-type antisense Bcl-X L . Prior to treatment with the oligonucleotides, HL-60 cells (5 x 10 5 /ml) were pretreated with PMA (20 ng/ml) for 16 h. The morpholino/DNA Special Delivery solution was prepared by mixing 2 M of the morpholino/DNA stock solution with water and the delivery reagent (ethoxylated polyethylenimine (EPEI)), and incubating at room temperature for 393 20 min according to the manufacturer's instructions. After 20 min, serum-free medium was added and the mixture vortexed. Medium from HL-60 cells (5 x 10 5 /ml) was removed and the complete delivery solution was added. After 3 h incubation, the complete delivery solution was removed and replaced with fresh medium containing 20 ng/ml PMA. Cell Viability was determined on days 3, 5 and 7 using trypan blue exclusion. For each timepoint, a total of 100 cells was counted in triplicate and viabilities were presented as the mean ± standard deviation.
Results
Induction of monocytic and granulocytic differentiation of HL-60 cells
To induce monocytic differentiation of HL-60 cells, PMA was added at a concentration of 20 ng/ml and differentiation was assessed by analysis of CD11b expression or by non-specific esterase (NSE) staining. Flow cytometric analysis of CD11b, a cell surface marker of myeloid differentiation 26 revealed that 40.5% cells and 96.7% of cells were differentiating along the monocytic lineage on days 1 and 3, respectively. A similar trend was seen when differentiation was assessed by cytochemical staining for NSE.
HL-60 cells treated with 5 M RA showed morphological and functional features characteristic of differentiated neutrophils. Granulocytic differentiation was assessed by expression of the CD11b marker and by nitroblue tetrazolium (NBT) reduction. Analysis of CD11b expression revealed that only 11.9% of cells stained positive for CD11b marker on day 1, with more cells differentiating along the granulocytic lineage by day 5 (78.2%). Similar results were seen when differentiation was determined by NBT reduction.
Induction of apoptosis associated with differentiation
Cells undergoing granulocytic or monocytic differentiation have limited lifespans and undergo apoptosis concurrent with the differentiation process. [27] [28] [29] [30] Differentiation-induced cell death was first examined using trypan blue exclusion. As shown in Figure 1a , PMA-treated HL-60 cells initially maintain their viability to day 3 (88.3% viable). A decline in viability was only detected at later timepoints (72.5% and 63% viable on days 5 and 7, respectively). In contrast, RAtreated HL-60 cells, although slower to stain positive for CD11b, exhibited a dramatic decline in viability as early as day 3 (68.5% viable) and 5 (31.3% viable). By day 7, less than 10% of RA-treated cells were viable (Figure 1a) . Similar results were obtained when apoptosis was examined by the DNA fragmentation or terminal deoxynucleotidyltransferase dUTP nick end labeling (TUNEL) assay (Figure 1b) . Thus, PMAtreated HL-60 cells (monocytic differentiation), although appearing to undergo more rapid differentiation, are comparatively longer-lived than cells undergoing RA-induced granulocytic differentiation. This is consistent with what has been observed by others, 22, 30 and with what is known to occur in vivo.
Activation of caspase-3 and expression of Bcl-2 and Bcl-X L during myeloid differentiation
One possible explanation for the longer lifespans of monocytic vs granulocytic cells may be lineage-specific differences
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Figure 1
Induction of apoptosis associated with differentiation. in the regulation of apoptosis pathways. We therefore examined the expression and activation of key apoptosis regulatory proteins during monocytic and granulocytic differentiation.
Caspases are activated during apoptosis by proteolytic cleavage of the precursor forms to smaller enzymatically active complexes. 6 Thus, the loss of procaspase forms indicates that caspase activation has occurred. As shown in Figure  2a and b, loss of procaspase-3 was observed during monocytic as well as granulocytic differentiation, with a delayed loss occurring in PMA-treated cells compared to RA-treated cells. To confirm the activation of caspase-3 during myeloid differentiation, we directly measured the enzymatic activity of caspase-3 at various timepoints during the differentiation process using a colorimetric assay. In agreement with our Western blotting results (showing a loss of procaspase-3), caspase-3 activity was found to increase to a much higher degree in RA-treated cells compared to PMA-treated cells (Figure 3a  and b) . By day 1 of RA treatment, caspase-3 activity had increased two-fold, and continued to rise thereafter ( Figure  3b ). By contrast, during induction of monocytic differentiation by PMA, relatively little, if any, increase in caspase-3 activity was observed at timepoints prior to day 7 (Figure 3a) . Thus, more rapid and potent activation of caspase-3 may contribute to the shorter lifespan of granulocytic cells. The activation of caspase-3 and other executioner caspases is regulated by members of the Bcl-2 protein family. 11, 12, 31 We therefore studied the expression of two anti-apoptotic members of the Bcl-2 protein family, Bcl-2 and Bcl-X L , which are known to potently inhibit caspase activation. 10 In agreement with a previous report, 22 we found that expression of the antiapoptotic protein Bcl-2 was downregulated during monocytic as well as granulocytic differentiation (data not shown).
The upregulation of Bcl-X L expression has been previously reported during monocytic differentiation. 22 We therefore compared the expression of Bcl-X L during monocytic differentiation with that observed during granulocytic differentiation. As shown in Figure 4 , proliferating HL-60 cells express low levels of Bcl-X L . However, following PMA treatment there is a dramatic upregulation of Bcl-X L protein. By contrast, no increases in Bcl-X L expression were seen during RA-induced granulocytic differentiation; the levels of Bcl-X L protein during granulocytic differentiation remain the same as in untreated HL-60 cells (Figure 4 ). These findings suggest that upregulation of Bcl-X L may contribute to the reduced activation of caspase-3 we observed during monocytic differentiation when compared with granulocytic differentiation (Figures  2 and 3) .
Figure 3
Caspase-3 activation during monocytic and granulocytic differentiation. HL-60 cells were treated with PMA (a) or RA (b) and lysates were prepared at the indicated timepoints as described in Materials and methods. Caspase-3 activity was measured using DEVD-pNA as substrate. Absorbance values were read at 405 nm. Each datapoint represents the mean of triplicate samples. Error bars represent standard deviations. Similar results were observed in three independent experiments.
STAT3 is activated during monocytic differentiation
To explore the possible mechanism of Bcl-X L upregulation, we examined the expression and activation of the transcriptional activator STAT3. STAT3 has been linked to upregulation of Bcl-X L protein in other systems, 23, 32 and has also been shown to play a role in G-CSF-induced differentiation and hematopoeitic cell survival. 33, 34 To study STAT3 activation, immunoblotting was performed using an antibody which recognizes STAT3 protein that has become activated by phosphorylation of tyrosine 705. Treatment of HL-60 cells with PMA led to phosphorylation/activation of STAT3 by 4 h (Figure 5a ). This result was confirmed by immunoprecipitation of whole cell lysates with anti-STAT3 followed by immunoblotting with anti-phosphoSTAT3 (Tyr 705) (Figure 5b ). At the same time, immunoblotting for total STAT3 protein revealed no significant changes in STAT3 protein expression following PMA treatment (Figures 5a and b) . Further evidence of STAT3 activation was obtained by EMSA analysis of whole cell extracts (Figure 5c ). In contrast to treatment with DMSO, PMA treatment of HL-60 cells led to increased STAT3 DNA binding activity at 4 and 8 h. The presence of activated STAT3 in gel shift bands was verified by supershift analysis in the presence of anti-STAT3 antibody (Figure 5c ). Treatment with RA did not lead to STAT3 activation at any of the timepoints studied (Figure 5c ). Taken together, these findings suggest that STAT3
Figure 4
Effect of PMA or RA on Bcl-X L protein levels. Whole cell lysates from PMA-and RA-treated cells were prepared, then analyzed by immunoblotting with anti-Bcl-X L polyclonal antibody. Filters were stripped and reprobed with ␤-actin monoclonal antibody as a loading control. Upregulation of Bcl-X L was seen during PMA-induced monocytic differentiation while no change in Bcl-X L expression was seen on RA-induced granulocytic differentiation. Similar results were observed in three independent experiments. is activated during monocytic differentiation, and may play a role in the upregulation of Bcl-X L .
Expression of XIAP and survivin during myeloid differentiation
Members of the IAP protein family constitute an additional group of intracellular regulators of apoptosis. 15 We investigated the expression of two IAP family members, XIAP and survivin. The XIAP protein is expressed in most cell types and has been shown to bind and potently inhibit the activities of caspase-3, caspase-7 and caspase-9. [16] [17] [18] [19] Survivin, while it is not known to bind to caspases, is overexpressed in a variety of malignant cell types, including leukemic cells. 35, 36 Recent experiments have shown that treatment of myeloid leukemic cell lines and primary AML cultures with GM-CSF leads to upregulation of survivin expression, 36 indicating that cytokines may promote survival, in part, by increasing survivin protein levels. In our studies, we observed that XIAP protein levels were significantly elevated following PMA treatment (Figure 6a ). By contrast, RA treatment led to decreased XIAP expression (Figure 6a ). This differential regulation of XIAP expression is similar to that seen for Bcl-X L (Figure 4) , and therefore also may contribute to the differing lifespans of monocytic vs granulocytic cells.
A different story was seen when survivin expression was examined. Proliferating HL-60 cells were found to express high levels of survivin protein, and both monocytic and granulocytic differentiation impacted expression levels. Following treatment with PMA, loss of survivin expression was observed as early as day 1, with complete loss by day 5 (Figure 6b) . Examination of survivin expression at earlier timepoints (4, 8 and 12 h) indicated that survivin expression was reduced as early as 12 h after treatment with PMA (data not shown). In the case of granulocytic differentiation (RA treatment), a decline in survivin levels was first detected on day 3, and total Leukemia loss was seen by day 7 (Figure 6b) . It is doubtful, therefore, that changes in survivin levels account for differences in the lifespans of monocytic and granulocytic cells.
Importance of the MEK/ERK pathway in the expression of apoptosis regulatory proteins
Several studies have shown that the intracellular kinases ERK-1 and ERK-2 play a role in the differentiation of certain cell types, [37] [38] [39] [40] and may be important for myeloid differentiation. 41 ERK-1 and -2 become activated when they are phosphorylated by the kinases MEK-1 and MEK-2. 42, 43 Once activated ERK-1 and -2 influence gene transcription by phosphorylating and activating specific transcription factors. 44, 45 To investigate the role of the MEK/ERK pathway in regulating the expression of anti-apoptotic molecules during myeloid differentiation, we examined the impact of U0126, a specific inhibitor of MEK-1 and MEK-2. 46 Pretreatment of HL-60 cells for 2 h with 5 M of U0126 was found to potently inhibit upregulation of Bcl-X L during monocytic differentiation (Figure 7a ). No effect of U0126 on Bcl-X L expression was observed during granulocytic differentiation (Figure 7b ). In the case of XIAP, inhibition of MEK-1/-2 by U0126 had relatively little impact on the observed upregulation during monocytic differentiation or the downregulation of XIAP during granulocytic differentiation (Figure 7a and b) . Taken together, these results indicate that the levels of Bcl-X L , but not XIAP, are regulated by MEK/ERKdependent pathways during myeloid differentiation.
Bcl-X L and XIAP are important for the longevity of monocytic cells
To determine whether the upregulation of Bcl-X L ( Figure 4) and XIAP ( Figure 6 ) observed during monocytic differentiation of HL-60 cells contributes to the longer lifespan of these cells, we examined the impact of antisense oligonucleotides. Morpholino antisense oligonucleotides directed against the translation start sites of Bcl-X L or XIAP mRNAs were added to cells 16 h after initiation of PMA treatment, and cell viabilities were measured at days 3, 5 and 7. Treatment with 2 M antisense Bcl-X L oligonucleotide had a dramatic effect on cell viability as early as day 3, decreasing viability from 90.2% (PMA alone) to 63.1% (PMA plus antisense-Bcl-X L ; Figure 8 ). By contrast, treatment with a mispaired Bcl-X L control oligonucleotide had little impact on cell viability, relative to cells treated with PMA alone. Antisense XIAP oligonucleotide (2 M) also markedly affected the survival of monocytic cells, with viability dropping to 56.4% and 22.8% by days 3 and 7, respectively. These results clearly indicate that upregulation of Bcl-X L and XIAP plays an important role in maintaining the survival of monocytic lineage cells.
Discussion
Granulocytes and monocytes, although derived from common myeloid progenitors, exhibit substantial differences in lifespans. In vivo, mature neutrophils have a half-life of approximately 6 h while monocytes are longer-lived. 47, 48 To determine the molecular mechanisms that are responsible for these differing lifespans we examined potential differences in the expression and activation of key apoptosis regulatory molecules during monocytic and granulocytic differentiation. Activation of STAT3 during monocytic differentiation. (a) Cells were treated with PMA and whole cell lysates were harvested at varying timepoints. Protein aliquots (50 g/lane) were electrophoresed on 10% SDS/PAGE gels and transferred to nitrocellulose membranes. The filters were probed with anti-phospho-STAT3 monoclonal antibody or anti-total STAT3 monoclonal antibody. Similar results were obtained in three independent experiments. (b) Cells were treated with PMA and whole cell lysates were harvested at varying timepoints as described in Materials and methods. Total STAT3 protein was immunoprecipitated from lysates (500 g) by incubation overnight with anti-STAT3 antibody. The resulting immune complexes were then electrophoresed on an 8% SDS-PAGE gel, transferred to nitrocellulose, and probed with antiphospho-STAT3 antibody. Subsequently, the filter was stripped and reprobed with anti-total STAT3 antibody. Similar results were obtained in two independent experiments. (c) Cells were treated with PMA or DMSO and whole cell extracts prepared as described in Materials and methods at the timepoints indicated. Lysates from U937 cells stimulated with G-CSF (300 ng/ml) for 15 min were used as a positive control for STAT3 binding activity. Binding reactions containing 45 g of sample protein and radiolabeled hSIE oligonucleotide were analyzed by EMSA. Supershift studies were carried out by the addition of anti-STAT3 antibody for 1 h prior to the addition of the radiolabeled probe. The resulting gels were dried and exposed to film. The location of the STAT3 gel-shifted and super-shifted bands is indicated.
PMA was used to induce monocytic differentiation and retinoic acid was used to induce neutrophilic differentiation of HL-60 cells. During the course of both monocytic and granulocytic differentiation, the differentiating cells showed evidence of apoptosis, including fragmentation of genomic DNA and loss of cell viability. The degree of apoptosis was proportional to the increase in mature, differentiated cells, consistent with earlier observations by Martin et al 28 and Solary et al. 30 Notably, HL-60 cells differentiating along the granulocytic lineage underwent apoptosis earlier than cells in the monocytic lineage.
Since caspase-3 is the key executioner caspase responsible for the demise of apoptotic cells, we studied the activation of this enzyme during the processes of monocytic and granulocytic differentiation. Both immunoblotting analyses and measurements of caspase-3 activity showed that caspase-3 activation was delayed and less robust in monocytic vs granulocytic cells. Previous studies have shown that caspase-3 activation is potently inhibited by the Bcl-2 family members, Bcl-X L and Bcl-2.
10,49 Therefore, we also examined expression levels of anti-apoptotic Bcl-X L and Bcl-2 during the course of differentiation. While no change in Bcl-X L levels were observed during granulocytic differentiation, the levels of this protein were dramatically upregulated during monocytic differentiation. This finding is consistent with studies showing increased expression of Bcl-X L during monocytic but not granulocytic differentiation of CD34 + hematopoietic progenitor cells, 22 and indicates that elevated Bcl-X L may contribute to the enhanced lifespan of monocytic lineage cells. An important role for Bcl-X L in maintaining the survival of hematopoietic progenitors is also supported by gene knockout studies. Targeted disruption of the bcl-X gene in mice results in massive apoptotic death of hematopoietic progenitors and gestational death of the animals. 50 With respect to Bcl-2, we observed downregulation of the protein during HL-60 cell differentiation, with no significant differences between monocytic and granulocytic differentiation.
In addition to a potential role for Bcl-X L , our studies also suggest a role for XIAP protein in sustaining monocytic cell survival. XIAP is known to inhibit caspase-3 activation by binding and inhibiting the activity of the upstream caspase, caspase-9.
18,19 XIAP can also directly bind to activated caspase-3 and inhibit its activity. 16, 17 We observed that, similar to Bcl-X L , the levels of XIAP were increased dramatically during monocytic, but not granulocytic, differentiation. Thus, the reduced activation and activity of caspase-3 seen in monocytic cells may be due to the action of both Bcl-X L and XIAP. By inhibiting caspase-3 activation and activity, Bcl-X L and XIAP likely delay apoptosis and promote the longer lifespan of monocytic lineage cells.
In an effort to delineate the upstream signaling pathways that control the expression and activation of apoptosis regulatory proteins, we examined the involvement of MEK/ERK signaling. The MEK/ERK pathway is known to play an important role in the differentiation of certain cell types. Neuronal differentiation of rat PC12 cells, as well as the maturation of thymocytes, has been shown to depend on sustained activation of the MEK/ERK pathway. 37, 38 The differentiation of K562 cells along the megakaryocytic lineage has also been shown to require MEK/ERK signaling, 39 and we have observed that MEK/ERK signaling is important for the myeloid differentiation of HL-60 cells. 41 Interestingly, inhibition of the MEK/ERK pathway using the MEK inhibitor, U0126, dramatically inhibited upregulation of Bcl-X L during monocytic differentiation. By contrast, upregulation of XIAP protein during monocytic differentiation was not significantly altered by U0126. This suggests that Bcl-X L and XIAP are regulated by distinct pathways during monocytic differentiation. Perhaps XIAP levels may be regulated by the phosphatidylinositol 3-kinase pathway, which is known to play an important role in hematopoietic cell survival. [51] [52] [53] [54] Previous studies have shown that STAT proteins, or signal transducers and activators of transcription, play important roles in the proliferation and survival of hematopoietic cells by mediating the effects of growth factors, cytokines and horLeukemia mones. [32] [33] [34] 55, 56 STATs are activated by tyrosine phosphorylation, which leads to dimerization and translocation to the nucleus. In the nucleus STATs bind to specific DNA sequences and bring about the transcription of specific genes. Recent studies have suggested a link between induction of the anti-apoptotic gene bcl-X and STATs. Consensus binding sites for the STAT3 and STAT5 proteins have been identified in the bcl-X promoter, 23, 57 and a dominant-negative form of STAT3 was shown to block IL-6-induced activation of bcl-X gene transcription. 32 In addition, dominant-negative STAT5 suppresses erythropoietin-induced transcription of the bcl-X gene. 58 Our observation of STAT3 activation during monocytic differentiation of HL-60 cells supports a role for STAT3 activation in Bcl-X L upregulation during myeloid differentiation. Whether STAT3 also induces the transcription of additional genes, such as XIAP, that may contribute to the enhanced lifespan of monocytic cells remains to be determined.
The differential expression patterns of two apoptosis regulatory proteins, Bcl-X L and XIAP, were the key differences observed between HL-60 cells differentiating along the monocytic and granulocytic lineages. While Bcl-X L levels remained unchanged during RA-induced granulocytic differentiation, this protein was markedly upregulated during PMA-induced monocytic differentiation. XIAP expression was rapidly downregulated in granulocytic lineage cells while there was a significant increase in XIAP levels in monocytic lineage cells. The possible role of Bcl-X L and XIAP upregulation in promoting the longer lifespan of monocytic lineage cells was investigated using antisense oligonucleotides. The dramatic loss in monocytic cell viability on treatment with antisense Bcl-X L or XIAP confirmed that both of these proteins are important for the survival of monocytic lineage cells.
In summary, there are lineage-specific differences in the expression and activation of apoptotic regulatory proteins that contribute to the longer lifespan of monocytic cells. The delayed activation of caspase-3 observed during monocytic differentiation could be explained by the increased expression of Bcl-X L and XIAP. The signaling pathways that regulate the expression of Bcl-X L and XIAP, however, appear to be different, with Bcl-X L being dependent on MEK signaling and XIAP
Figure 7
U0126 inhibits Bcl-X L upregulation during monocytic differentiation. HL-60 cells were pretreated with U0126 (5 M) for 2 h followed by treatment with PMA (a) or RA (b) for 72 h. Whole cell lysates were prepared on day 3 and proteins (25 g/lane) were electrophoresed on 12.5% SDS/PAGE gels and transferred to nitrocellulose membranes. Filters were probed with anti-Bcl-X L or anti-XIAP antibodies. The filters were then stripped and reprobed with ␤-actin monoclonal antibody. Similar results were obtained in two independent experiments.
being MEK-independent. STAT3 activation was also observed during monocytic differentiation and may play a role in the upregulation of Bcl-X L expression. It is also possible that MEK/ERK activation promotes STAT3 activation during PMAinduced monocytic differentiation. Thus, in one potential model, induction of monocytic differentiation by PMA leads to activation of the MEK/ERK pathway, followed by phosphorylation/activation of STAT3 by a MEK/ERK-dependent mechanism. The activation of STAT3 could then lead to upregulation of Bcl-X L expression, which, in concert with upregulated XIAP, would reduce the capacity to activate caspase-3 or inhibit caspase-3 that is already activated. A delay in caspase-3 activation or the inhibition of this enzyme would result in a significant delay in the onset of differentiationinduced apoptosis. Further studies will be needed to critically examine this model, and to assess the potential role that other signaling pathways, including the p38, JNK, and PI3-K pathways, play in determining the differing lifespans of myeloid lineage cells. 
